BRPI0412909A - uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer - Google Patents
uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncerInfo
- Publication number
- BRPI0412909A BRPI0412909A BRPI0412909-1A BRPI0412909A BRPI0412909A BR PI0412909 A BRPI0412909 A BR PI0412909A BR PI0412909 A BRPI0412909 A BR PI0412909A BR PI0412909 A BRPI0412909 A BR PI0412909A
- Authority
- BR
- Brazil
- Prior art keywords
- manufacture
- cancer medicine
- parp activity
- inhibiting parp
- rnai
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
"USO DE RNAI INIBINDO ATIVIDADE DE PARP PARA A FABRICAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE CáNCER". A presente invenção se refere ao uso de um agente que inibe a atividade de uma enzima que media reparo de uma quebra do filamento do DNA na fabricação de um medicamento para o tratamento de doenças causadas por um defeito em um gene que media a recombinação homóloga.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0317466.1A GB0317466D0 (en) | 2003-07-25 | 2003-07-25 | Use |
GB0317466.1 | 2003-07-25 | ||
PCT/GB2004/003235 WO2005012524A1 (en) | 2003-07-25 | 2004-07-23 | Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0412909A true BRPI0412909A (pt) | 2006-09-26 |
BRPI0412909B1 BRPI0412909B1 (pt) | 2022-04-12 |
Family
ID=27772701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412909-1A BRPI0412909B1 (pt) | 2003-07-25 | 2004-07-23 | Uso de um inibidor de poli (adp-ribose) polimerase 1 (parp-1) para a fabricação de um medicamento para o tratamento de células de câncer defeituosas em recombinação homóloga |
Country Status (19)
Country | Link |
---|---|
US (5) | US8859562B2 (pt) |
EP (1) | EP1649017B2 (pt) |
JP (3) | JP5519097B2 (pt) |
KR (1) | KR101136702B1 (pt) |
CN (3) | CN1856313B (pt) |
AT (1) | ATE516353T1 (pt) |
AU (1) | AU2004261779B2 (pt) |
BR (1) | BRPI0412909B1 (pt) |
CA (1) | CA2533423C (pt) |
DK (1) | DK1649017T4 (pt) |
ES (1) | ES2367433T5 (pt) |
GB (2) | GB0317466D0 (pt) |
HK (2) | HK1094006A1 (pt) |
NO (1) | NO338398B1 (pt) |
NZ (1) | NZ545307A (pt) |
PL (1) | PL1649017T5 (pt) |
PT (1) | PT1649017E (pt) |
WO (1) | WO2005012524A1 (pt) |
ZA (1) | ZA200601386B (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
JP2007501857A (ja) | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | 四環系ベンズアミド誘導体およびその使用方法 |
CA2533332C (en) | 2003-07-25 | 2012-01-10 | Cancer Research Technology Limited | Therapeutic compounds |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
SG150548A1 (en) * | 2003-12-01 | 2009-03-30 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
WO2006078503A2 (en) * | 2005-01-07 | 2006-07-27 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
WO2006078711A2 (en) | 2005-01-19 | 2006-07-27 | Mgi Gp, Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
AU2006219023A1 (en) | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic Amino and Carboxamido Compounds and methods of use thereof |
RU2008110955A (ru) | 2005-08-24 | 2009-09-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Инденоизохинолиноновые аналоги и способы их применения |
AU2006318226A1 (en) * | 2005-11-25 | 2007-05-31 | Pharma Mar, S.A. Sociedad Unipersonal | Use of PARP-1 inhibitors |
AU2007325900A1 (en) * | 2006-10-20 | 2008-06-05 | Dnar, Inc. | DNA damage repair inhibitors and methods for treating cancer |
PT2099442E (pt) * | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
CA2677046A1 (en) | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
GB0707556D0 (en) * | 2007-04-19 | 2007-05-30 | Isis Innovation | Treatment for cancer |
EP2184352B1 (en) | 2007-06-20 | 2015-09-09 | Saitama Medical University | Double-stranded nucleic acid molecule, cancer cell proliferation inhibitor and pharmaceutical agent suitable for prevention or treatment of uterine cancer, breast cancer and bladder cancer |
WO2009027650A1 (en) * | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
RU2485122C2 (ru) | 2007-10-03 | 2013-06-20 | Эйсэй Инк. | Соединения и композиции, ингибирующие parp, и способы их применения |
JP5683261B2 (ja) | 2008-03-11 | 2015-03-11 | 学校法人 埼玉医科大学 | 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |
KR20110128785A (ko) * | 2008-10-24 | 2011-11-30 | 매그나켐 인터내셔널 레버러토리즈 아이엔씨 | Rad9와 선택적으로 상호작용하는 화합물들의 스크리닝방법 |
US20110097329A1 (en) | 2009-06-26 | 2011-04-28 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
US8268550B2 (en) * | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
US8435961B2 (en) * | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
DK2609216T3 (en) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
WO2013052006A1 (en) * | 2010-10-07 | 2013-04-11 | Agency For Science, Technology And Research (A*Star) | Parp-1 inhibitors |
EP2734199B1 (en) | 2011-07-22 | 2022-11-16 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
EP2817630B1 (en) * | 2012-02-23 | 2018-07-11 | Children's Medical Center Corporation | Methods for predicting anti-cancer response |
ES2595240T3 (es) | 2012-07-09 | 2016-12-28 | Lupin Limited | Derivados de tetrahidroquinazolinona como inhibidores de PARP |
WO2014172458A1 (en) * | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
CN105793437B (zh) * | 2013-09-23 | 2020-12-15 | 芝加哥大学 | 关于dna损伤制剂用于癌症治疗的方法和组合物 |
WO2015118156A1 (en) * | 2014-02-07 | 2015-08-13 | Vib Vzw | Inhibition of neat1 for treatment of solid tumors |
US9889141B2 (en) | 2014-10-14 | 2018-02-13 | Institute For Cancer Research | Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
ES2964607T3 (es) | 2015-07-17 | 2024-04-08 | Pacylex Pharmaceuticals Inc | Silenciamiento epigenético de NMT2 |
KR20180059922A (ko) | 2015-10-02 | 2018-06-05 | 유니버시티 오브 코펜하겐 | 히스톤 리더 도메인을 차단하는 소분자 |
ES2754785T3 (es) * | 2016-02-22 | 2020-04-20 | Caribou Biosciences Inc | Procedimientos de modulación de resultados de reparación de ADN |
MA50677A (fr) * | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
MA47206A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
CN107058233A (zh) * | 2017-05-03 | 2017-08-18 | 上海长海医院 | 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法 |
CN108048465A (zh) * | 2017-12-20 | 2018-05-18 | 李风玲 | 一种抑制PARP基因用于治疗乳腺癌的siRNA |
WO2019133864A1 (en) | 2017-12-29 | 2019-07-04 | Accutar Biotechnology | DUAL INHIBITORS OF PARP1 and CDK |
CN111989137A (zh) | 2018-01-05 | 2020-11-24 | 赛博克萨1公司 | 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法 |
WO2020198298A1 (en) * | 2019-03-25 | 2020-10-01 | Cyteir Therapeutics, Inc. | Combinations of rad51 and parp inhibitors |
PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
CR20220057A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
WO2021133886A1 (en) | 2019-12-23 | 2021-07-01 | Accutar Biotechnology | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
IL297537A (en) | 2020-04-28 | 2022-12-01 | Rhizen Pharmaceuticals Ag | New compounds useful as poly (adp-ribose) polymerase (parp) inhibitors |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
CN114836472A (zh) * | 2021-02-01 | 2022-08-02 | 中国人民解放军军事科学院军事医学研究院 | PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用 |
AU2022255809A1 (en) | 2021-04-08 | 2023-10-26 | Incozen Therapeutics Pvt. Ltd. | Inhibitors of poly(adp-ribose) polymerase |
CA3219248A1 (en) | 2021-05-18 | 2022-11-24 | Hyun Ju Cha | Parp inhibitor-resistant cancer therapeutic agent |
WO2023089032A1 (en) * | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484951A (en) | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
US5098861A (en) | 1991-01-08 | 1992-03-24 | Unitrode Corporation | Method of processing a semiconductor substrate including silicide bonding |
US5464871A (en) | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
EP0600831A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phthalazinonderivate |
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
AU8784698A (en) * | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
EP1140936B1 (en) * | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
KR20030020450A (ko) * | 2000-08-08 | 2003-03-08 | 사노피-신델라보 | 벤지미다졸 유도체, 그의 제조 방법 및 치료적 용도 |
IL155645A0 (en) | 2000-10-30 | 2003-11-23 | Kudos Pharm Ltd | Phthalazinone derivatives |
US6664269B2 (en) | 2001-05-08 | 2003-12-16 | Maybridge Plc | Isoquinolinone derivatives |
US7072771B2 (en) * | 2001-06-07 | 2006-07-04 | University Of Kentucky Research Foundation | Selective PARP-1 targeting for designing chemo/radio sensitizing agents |
US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
ES2357057T3 (es) | 2002-04-30 | 2011-04-15 | Kudos Pharmaceuticals Limited | Derivados de ftalazinona. |
WO2004008976A1 (en) | 2002-07-19 | 2004-01-29 | Osteotech, Inc. | Chisels and procedure for insertion of spinal implant in a spinal disc space |
GB2415430B (en) * | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7176188B2 (en) | 2003-05-07 | 2007-02-13 | UniversitéLaval | Method of lethally sensitizing human and animal cells |
CA2533332C (en) * | 2003-07-25 | 2012-01-10 | Cancer Research Technology Limited | Therapeutic compounds |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
SG150548A1 (en) | 2003-12-01 | 2009-03-30 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
-
2003
- 2003-07-25 GB GBGB0317466.1A patent/GB0317466D0/en not_active Ceased
-
2004
- 2004-07-23 AT AT04743564T patent/ATE516353T1/de active
- 2004-07-23 US US10/555,507 patent/US8859562B2/en active Active
- 2004-07-23 CA CA2533423A patent/CA2533423C/en active Active
- 2004-07-23 DK DK04743564.9T patent/DK1649017T4/da active
- 2004-07-23 KR KR1020067001650A patent/KR101136702B1/ko active Protection Beyond IP Right Term
- 2004-07-23 PT PT04743564T patent/PT1649017E/pt unknown
- 2004-07-23 NZ NZ545307A patent/NZ545307A/en unknown
- 2004-07-23 JP JP2006520907A patent/JP5519097B2/ja active Active
- 2004-07-23 GB GB0603874A patent/GB2419882B/en active Active
- 2004-07-23 BR BRPI0412909-1A patent/BRPI0412909B1/pt active IP Right Grant
- 2004-07-23 EP EP04743564.9A patent/EP1649017B2/en active Active
- 2004-07-23 WO PCT/GB2004/003235 patent/WO2005012524A1/en active Application Filing
- 2004-07-23 CN CN2004800273183A patent/CN1856313B/zh active Active
- 2004-07-23 ES ES04743564.9T patent/ES2367433T5/es active Active
- 2004-07-23 CN CN201210332472.8A patent/CN102935230B/zh active Active
- 2004-07-23 AU AU2004261779A patent/AU2004261779B2/en active Active
- 2004-07-23 PL PL04743564T patent/PL1649017T5/pl unknown
- 2004-07-23 CN CN2004800272941A patent/CN1856572B/zh active Active
-
2006
- 2006-02-16 ZA ZA200601386A patent/ZA200601386B/en unknown
- 2006-02-24 NO NO20060906A patent/NO338398B1/no unknown
-
2007
- 2007-01-10 HK HK07100334.8A patent/HK1094006A1/xx unknown
-
2011
- 2011-11-11 JP JP2011246988A patent/JP5547164B2/ja active Active
-
2013
- 2013-07-16 JP JP2013147532A patent/JP5848728B2/ja active Active
- 2013-08-12 HK HK13109407.3A patent/HK1182016A1/zh unknown
-
2014
- 2014-07-02 US US14/322,759 patent/US20150005327A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,459 patent/US20180000822A1/en not_active Abandoned
-
2019
- 2019-10-10 US US16/598,808 patent/US20200237762A1/en not_active Abandoned
-
2021
- 2021-11-16 US US17/528,034 patent/US20220062286A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412909A (pt) | uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer | |
EA201300987A1 (ru) | Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2 | |
IN2014CN03465A (pt) | ||
CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
WO2009045356A8 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
BRPI0518228B8 (pt) | inibidores de cinesina mitótica e uso dos mesmos | |
CR10730A (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
EA201690111A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
CL2011003346A1 (es) | Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente. | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
NI201200029A (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
BRPI0511477A (pt) | compostos e composições como moduladores de ppar | |
ECSP077235A (es) | Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa | |
GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
UY29640A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos. | |
WO2005116210A3 (de) | Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs | |
TW200734335A (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |